an estimated 150-200 million people worldwide are infected with hepatitis c. prevalence is higher in some countries in asia and africa. only limited information about the epidemiology of hepatitis c virus (hcv) infection especially in females is available. the aim of this study is to determine the prevalence of anti-hcv antibodies and the possible factors for transmission in the female populati...

Fowl adenoviruses (FAdV), detected during routine diagnostic investigations from 38 countries (5 continents) over a decade, were partially sequenced and grouped by phylogenetic analysis. The partial polymerase gene nucleotide sequences of the 365 fowl adenovirus isolates resulted in following species distribution: 11% FAdV-A; 3% FAdV-B; 2% FAdV-C; 34% FAdV-D; 50% FAdV-E. Noticeably, only 79 str...

background: in patients with hepatitis b and c, environmental factors such as smoking and alcohol can cause liver fibrosis progression. but opium effects on liver fibrosis progression are not clear. this study was designed to assess the relationship of opium user and liver fibrosis progression. methods: in this case-control study, sixty patients in hepatitis b group and sixty patients in hepati...

background viral hepatitis is a systemic infection affecting the liver predominantly. almost all cases of acute viral hepatitis are caused by one of five viral agents: hav, hbv, hcv, hdv and hev. the present study aimed to find out the frequency of various forms of viral hepatitis (hav, hbv, and hcv), route of transmission, the history of vaccination against hepatitis b, and clinical findings i...

Acute hepatitis patients admitted to a referral centre from January 1995 through December 1995 were studied to determine the seroprevalence of the hepatitis viruses and related risk factors. Of the 434 patients with acute viral hepatitis, the episodes due to hepatitis A, B, C, D, and non-A, non-B, non-C, (non-ABC) were 214 (49.3%), 163 (37.6%), 7 (1.6%), 0 (0%), and 50 (11.5%), respectively. Ac...

patients and methods consecutive twenty chc patients aged ≥ 65 years were enrolled in this pilot study. fifteen patients met the inclusion criteria and received peg-ifn/ ribavirin therapy combined with alfacalcidol. four-week lead-in of oral alfacalcidol was conducted, and it was subsequently and concurrently administered in peg-ifn/ ribavirin combination therapy (vitamin d group). age, gender,...